Check-Cap Ltd. (MBAI) - Net Assets
Based on the latest financial reports, Check-Cap Ltd. (MBAI) has net assets worth $3.44 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.49 Million) and total liabilities ($4.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MBAI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.44 Million |
| % of Total Assets | 45.91% |
| Annual Growth Rate | -48.97% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 36.95 |
Check-Cap Ltd. - Net Assets Trend (2021–2025)
This chart illustrates how Check-Cap Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore MBAI total asset value for the complete picture of this company's asset base.
Annual Net Assets for Check-Cap Ltd. (2021–2025)
The table below shows the annual net assets of Check-Cap Ltd. from 2021 to 2025. For live valuation and market cap data, see Check-Cap Ltd. (MBAI) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.44 Million | +337.03% |
| 2024-12-31 | $-1.45 Million | -106.12% |
| 2023-12-31 | $23.69 Million | -42.66% |
| 2022-12-31 | $41.31 Million | -18.50% |
| 2021-12-31 | $50.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Check-Cap Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5768500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $83.92 Million | 2441.61% |
| Other Components | $85.39 Million | 2484.41% |
| Total Equity | $3.44 Million | 100.00% |
Check-Cap Ltd. Competitors by Market Cap
The table below lists competitors of Check-Cap Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AirIQ Inc
V:IQ
|
$11.16 Million |
|
Admiralty Resources NL
AU:ADY
|
$11.16 Million |
|
pferdewetten.de AG
XETRA:EMH
|
$11.17 Million |
|
CBL International Limited Ordinary Shares
NASDAQ:BANL
|
$11.17 Million |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
$11.16 Million |
|
Sarama Resources Ltd
AU:SRR
|
$11.14 Million |
|
Bioatla Inc
NASDAQ:BCAB
|
$11.14 Million |
|
i2S SA
PA:ALI2S
|
$11.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Check-Cap Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,450,000 to 3,437,000, a change of 4,887,000.
- Net income of 4,140,000 contributed positively to equity growth.
- Other factors increased equity by 747,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.14 Million | +120.45% |
| Other Changes | $747.00K | +21.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Check-Cap Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.21x to 3.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $8.94 | $1.86 | x |
| 2022-12-31 | $7.28 | $1.86 | x |
| 2023-12-31 | $4.05 | $1.86 | x |
| 2024-12-31 | $-0.25 | $1.86 | x |
| 2025-12-31 | $0.55 | $1.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Check-Cap Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 120.45%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.18x
- Recent ROE (120.45%) is above the historical average (-6.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -33.94% | 0.00% | 0.00x | 1.10x | $-22.27 Million |
| 2022 | -46.25% | 0.00% | 0.00x | 1.10x | $-23.24 Million |
| 2023 | -74.17% | 0.00% | 0.00x | 1.06x | $-19.94 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.00 Million |
| 2025 | 120.45% | 0.00% | 0.00x | 2.18x | $3.80 Million |
Industry Comparison
This section compares Check-Cap Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,087,739,377
- Average return on equity (ROE) among peers: -26.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Check-Cap Ltd. (MBAI) | $3.44 Million | -33.94% | 1.18x | $11.16 Million |
| Agilent Technologies Inc (A) | $5.84 Billion | 21.21% | 0.84x | $32.49 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $6.75 Million |
| Applied DNA Sciences Inc (APDN) | $-11.94 Million | 0.00% | 0.00x | $3.99 Million |
| Biodesix Inc (BDSX) | $19.73 Million | -218.78% | 2.86x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $7.29 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $3.57 Billion |
| Burning Rock Biotech Ltd (BNR) | $580.83 Million | -59.68% | 0.52x | $143.84 Million |
| CareDx Inc (CDNA) | $465.88 Million | -6.58% | 0.22x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $-1.45 Million | 0.00% | 0.00x | $9.42 Million |
About Check-Cap Ltd.
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.